Cargando…

Treating thalassemia major-related iron overload: the role of deferiprone

Over the last 20 years, management for thalassemia major has improved to the point where we predict that patients’ life expectancy will approach that of the normal population. These outcomes result from safer blood transfusions, the availability of three iron chelators, new imaging techniques that a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berdoukas, Vasilios, Farmaki, Kallistheni, Carson, Susan, Wood, John, Coates, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3480237/ https://www.ncbi.nlm.nih.gov/pubmed/23112580 http://dx.doi.org/10.2147/JBM.S27400

Ejemplares similares

Rapid iron loading in a pregnant woman with transfusion-dependent thalassemia after brief cessation of iron chelation therapy
por: Farmaki, Kallistheni, et al.
Publicado: (2008)

Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload
por: Smith, Gillian C, et al.
Publicado: (2011)

Combination Iron Chelation Therapy with Deferiprone and Deferasirox in Iron-Overloaded Patients with Transfusion-Dependent β-Thalassemia Major
por: Karami, Hossein, et al.
Publicado: (2017)

Prospective comparison on cardiac iron by MR in thalassemia major patients treated with combination deferipron-desferrioxamine versus deferipron and desferrioxamine in monoterapy
por: Pepe, Alessia, et al.
Publicado: (2011)

Estimates of the effect on hepatic iron of oral deferiprone compared with subcutaneous desferrioxamine for treatment of iron overload in thalassemia major: a systematic review
por: Caro, J Jaime, et al.
Publicado: (2002)

Efficacy and safety of combined oral iron chelation therapy with deferasirox and deferiprone in a patient with beta-thalassemia major and persistent iron overload
por: Alavi, Samin, et al.
Publicado: (2014)

Cardiac Function and Iron Chelation in Thalassemia Major and Intermedia: a Review of the Underlying Pathophysiology and Approach to Chelation Management
por: Aessopos, Athanasios, et al.
Publicado: (2009)

A T2* MRI prospective survey on heart iron in thalassemia major patients treated with sequential deferiprone-desferrioxamine versus deferipron and desferrioxamine in monotherapy
por: Pepe, Alessia, et al.
Publicado: (2011)

Biventricular dimensions and function in pediatric sickle-cell disease and thalassemia major patients without cardiac iron
por: Meloni, Antonella, et al.
Publicado: (2013)

Cardiac and hepatic iron and ejection fraction in thalassemia major: Multicentre prospective comparison of combined Deferiprone and Deferoxamine therapy against Deferiprone or Deferoxamine Monotherapy
por: Pepe, Alessia, et al.
Publicado: (2013)

A T2* MRI prospective survey on heart iron in thalassemia major patients treated with sequential deferipron-desferrioxamine versus deferasirox
por: Pepe, Alessia, et al.
Publicado: (2011)

A T2* MRI prospective survey on heart iron in thalassemia major patients treated with deferasirox versus deferiprone and desferrioxamine in monotherapy
por: Pepe, Alessia, et al.
Publicado: (2011)

Prevalence of iron overload complications among patients with β-thalassemia major treated at Dubai Thalassemia Centre
por: Belhoul, Khawla Mohammed, et al.
Publicado: (2013)

Chelation Therapy with Oral Solution of Deferiprone in Transfusional Iron-Overloaded Children with Hemoglobinopathies
por: Makis, Alexandros, et al.
Publicado: (2013)

The History of Deferiprone (L1) and the Paradigm of the Complete Treatment of Iron Overload in Thalassaemia
por: Kontoghiorghes, George J., et al.
Publicado: (2020)

Myocardial iron overload in thalassemia major. How early to check?
por: Meloni, Antonella, et al.
Publicado: (2014)

Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone
por: Porter, John B, et al.
Publicado: (2013)

Efficacy and Safety of Combined Deferiprone and Deferasirox in Iron-Overloaded Patients: A Systematic Review
por: Salem, Ahmed, et al.
Publicado: (2023)

Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β-thalassemia intermedia
por: Schmidt, Paul J, et al.
Publicado: (2015)

Treating iron overload in patients with non-transfusion-dependent thalassemia
por: Taher, Ali T, et al.
Publicado: (2013)

MRI prospective survey on cardiac and hepatic iron in transfusion-dependent thalassemia intermedia patients treated with desferrioxamine, deferiprone and deferasirox
por: Meloni, Antonella, et al.
Publicado: (2015)

How Early Can Myocardial Iron Overload Occur in Beta Thalassemia Major?
por: Yang, Gaohui, et al.
Publicado: (2014)

Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective
por: Galanello, Renzo
Publicado: (2007)

Deferiprone-induced arthropathy in thalassemia: MRI findings in a case
por: Chand, Gyan, et al.
Publicado: (2009)

Iron-overload-induced ferroptosis in mouse cerebral toxoplasmosis promotes brain injury and could be inhibited by Deferiprone
por: Wang, Chong, et al.
Publicado: (2023)

P1511: EFFICACY AND SAFETY OF COMBINATION IRON CHELATION THERAPY WITH DEFERIPRONE AND DEFERASIROX IN PATIENTS WITH Β-THALASSEMIA MAJOR: A SYSTEMATIC LITERATURE REVIEW
por: Piga, A., et al.
Publicado: (2022)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes
por: Taher, Ali T, et al.
Publicado: (2016)

Hepcidin gene polymorphisms and iron overload in β-thalassemia major patients refractory to iron chelating therapy
por: Zarghamian, Parinaz, et al.
Publicado: (2020)

Right ventricular volumes and function in thalassemia major patients in the absence of myocardial iron overload
por: Carpenter, John-Paul, et al.
Publicado: (2010)

Estimation of iron overloads using oral exfoliative cytology in beta-thalassemia major patients
por: Leekha, Swati, et al.
Publicado: (2016)

Liver Enzymes in Children with beta-Thalassemia Major: Correlation with Iron Overload and Viral Hepatitis
por: Salama, Khaled M., et al.
Publicado: (2015)

Iron overload assessment in β Thalassemia Major – is T2* Magnetic Resonance Imaging the answer?
por: Ali, Natasha
Publicado: (2017)

Iron overload and fragmented QRS in patients with Thalassemia major: Mechanisms, therapies, and new horizons
por: Karakulak, Uğur Nadir, et al.
Publicado: (2015)

Cardiac Magnetic Resonance Strain in Beta Thalassemia Major Correlates with Cardiac Iron Overload
por: Ansah, Deidra, et al.
Publicado: (2023)

Vitamin D levels and left ventricular function in beta-thalassemia major with iron overload
por: Pala, Mrudula, et al.
Publicado: (2023)

Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective
por: Bentley, Anthony, et al.
Publicado: (2013)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes
por: Kontoghiorghe, Christina N, et al.
Publicado: (2016)

Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior
por: Ansari, Shahla, et al.
Publicado: (2017)

Erratum to: Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective
por: Bentley, Anthony, et al.
Publicado: (2013)

Restoring the impaired cardiac calcium homeostasis and cardiac function in iron overload rats by the combined deferiprone and N-acetyl cysteine
por: Wongjaikam, Suwakon, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2lb84k7cjbuqn8pdjjegu051iq